Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.77M, +152.6% YoY · Filed Aug 14, 2026
Nuo Therapeutics, Inc. (AURX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.8 million and a net loss of $277,601. Free cash flow was -$489,502. As of Jun 30, 2026 it held $449,325 in cash and investments and $60,090 in total debt.
Revenue
$1.77M
+152.6% vs year-ago quarter
Net income
$-277,601
+57.3% vs year-ago quarter
Operating cash flow
$-236,475
-190.1% vs year-ago quarter
Free cash flow
$-489,502
-287.8% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
48.43M
+3.4% vs year-ago quarter
Net cash
$389,235
Q2 FY2026
Operating margin
-33.3%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- AURX (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1091596
- Former names
- Nuo Therapeutics, Inc (until Dec 23, 2014); CYTOMEDIX INC (until Oct 8, 2014); AUTOLOGOUS WOUND THERAPY INC (until Apr 10, 2000); AUTOLOGOUS WOUND TRERAPY INC (until Mar 23, 2000)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.8M | $1.3M | $1.1M | $1.0M | $700,202 |
| Operating income | -$166,552 | -$446,466 | -$579,338 | -$540,142 | -$652,022 |
| Net income | -$277,601 | -$618,466 | -$578,480 | -$537,919 | -$649,689 |
| Operating cash flow | -$236,475 | -$784,272 | -$422,646 | -$706,516 | $262,366 |
| Free cash flow | -$489,502 | -$785,119 | -$465,851 | -$706,516 | $260,699 |
| Total assets | $2.6M | $1.9M | $1.8M | $1.9M | $1.4M |
| Total liabilities | $4.2M | $3.3M | $2.8M | $2.3M | $2.2M |
| Stockholders' equity | -$1.5M | -$1.4M | -$956,559 | -$419,606 | -$824,561 |
| Cash and investments | $449,325 | $263,827 | $548,946 | $514,797 | $316,354 |
| Total debt | $60,090 | $78,949 | $97,346 | $114,692 | $131,608 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 3, 2026 | May 29, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 1001 Nuo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.